Relationship of Plasma Cell Infiltration Rates with ¹⁸F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Radionuclide Therapy Pub Date : 2025-02-07 DOI:10.4274/mirt.galenos.2024.78557

Özge Ulaş Babacan, Zekiye Hasbek, Hatice Terzi

{"title":"Relationship of Plasma Cell Infiltration Rates with 18F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma.","authors":"Özge Ulaş Babacan, Zekiye Hasbek, Hatice Terzi","doi":"10.4274/mirt.galenos.2024.78557","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to evaluate the relationship between the degree of bone marrow involvement, hematological parameters, and 18F-fluorodeoxyglucose (18F-FDG)-positron emission tomography/computed tomography (PET/CT) data in patients diagnosed with multiple myeloma.Methods: A total of 71 patients [19 females, 52 males, mean age 67 (36-83) years] who were diagnosed with multiple myeloma between 2014 and 2021, had not received any treatment yet, and underwent 18F-FDG-PET/CT for staging were included in the study.Results: No significant correlation was observed between bone marrow standardized uptake value (SUV)max and plasma cell infiltration (p=0.07). However, we found that patients with visually increased bone marrow counts also had higher plasma cell infiltration rates (p=0.037). No significant correlation was found between plasma cell infiltration rates and bone marrow SUVmax and systemic inflammatory index (SII) (p=0.187 and p=0.446, respectively). However, there was a significant correlation between the SUVmax of lytic lesions showing increased 18F-FDG uptake in bone and SII (p=0.025, r=0.330).Conclusion: We believe that 18F-FDG PET/CT may be an advantage over bone marrow biopsy in the diagnosis and evaluation of multiple myeloma recurrence and may prevent repeated bone marrow biopsies.","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"26-30"},"PeriodicalIF":0.9000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827519/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2024.78557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to evaluate the relationship between the degree of bone marrow involvement, hematological parameters, and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)-positron emission tomography/computed tomography (PET/CT) data in patients diagnosed with multiple myeloma.

Methods: A total of 71 patients [19 females, 52 males, mean age 67 (36-83) years] who were diagnosed with multiple myeloma between 2014 and 2021, had not received any treatment yet, and underwent ¹⁸F-FDG-PET/CT for staging were included in the study.

Results: No significant correlation was observed between bone marrow standardized uptake value (SUV)_max and plasma cell infiltration (p=0.07). However, we found that patients with visually increased bone marrow counts also had higher plasma cell infiltration rates (p=0.037). No significant correlation was found between plasma cell infiltration rates and bone marrow SUV_max and systemic inflammatory index (SII) (p=0.187 and p=0.446, respectively). However, there was a significant correlation between the SUV_max of lytic lesions showing increased ¹⁸F-FDG uptake in bone and SII (p=0.025, r=0.330).

Conclusion: We believe that ¹⁸F-FDG PET/CT may be an advantage over bone marrow biopsy in the diagnosis and evaluation of multiple myeloma recurrence and may prevent repeated bone marrow biopsies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.